Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-11-30
pubmed:abstractText
Growing evidence points toward the key role of angiogenesis in ovarian cancer. Granulosa cell tumor (GCT) does not seem to be an exception. Recent studies reporting the use of bevacizumab, a monoclonal antibody against the vascular epithelial growth factor, in recurrent GCT have shown encouraging results in terms of both symptoms control and response rate. This study presented the case of an adult-type GCT treated with neoadjuvant bevacizumab. To the best of the Authors' knowledge, this is the first report describing the use of an anti-angiogenic agent as neoadjuvant therapy in GCT. A further discussion on the results of this study and those previously published is also given.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1791-7530
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4767-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.
pubmed:affiliation
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. nibarren@uc.cl
pubmed:publicationType
Journal Article, Case Reports